* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Dish of the Day
Admissions:
None
Delistings:
None
Banquet Buffet****
London Stock Exchange: Main Market and AIM
Accsys Technologies 64.40p £176.62m (AXS.L)
The supplier of sustainable wood building materials provided a trading update for the five months ended 31 August. Accsys reported revenue of EUR 56.9m for the five months ended 31 August, down 6% from EUR 60.4m. Trading in the first five months of FY27 has started slower than expected due to inflationary pressures, interest rate increases, cautious purchasing patterns, delayed project activity and reduced consumer confidence. The Group experienced significant distributor destocking across all regions. The Group expects sales growth in H2 and anticipates a stronger second-half weighting to revenue and profit. FY27 adjusted EBITDA is expected to be EUR 21m–EUR 23m, ahead of the prior year.
B90 Holdings 4.60p £21.38m (B90.L)
The performance marketing and MarTech business for the global gaming industry announced its unaudited interim results for the six months ended 30 June. Revenue increased by approximately 38% to EUR 3.325m (H1 2025: EUR 2.407m), reflecting continued growth in marketing activities and increased activity across its partner base. Adjusted EBITDA remained positive at EUR 0.31m (H1 2025: EUR 0.30m) and cash and cash equivalents increased to EUR 1.47m at 30 June, compared with EUR 0.97m at 31 December 2025 and EUR 0.40m at 30 June 2025. The Board remains confident in the Group's prospects for the remainder of the year and based on current trading, expects the Group to deliver results in line with management expectations for the full year.
Cambridge Cognition Holdings 27.50p £14.86m (COG.L)
The neuroscience technology Company and C2N Diagnostics announced a partnership with The Alzheimer's Trust, a newly formed subsidiary of The Cancer Screening Trust, on World Alzheimer’s Day to address the urgent and growing burden of Alzheimer's disease and related dementias in the UK. The collaboration creates an integrated, scalable pathway for earlier and more accurate diagnosis of Alzheimer's disease and related dementias in the UK. The Alzheimer’s Trust said this collaboration with C2N and Cambridge Cognition enables them to offer the best tests available to those in need and to address the issue with sensitivity and integrity.
CRISM Therapeutics Corporation 9.75p £7.72m (CRTX.L)
The clinical-stage drug delivery Company focused on the localised and sustained delivery of chemotherapy drugs announced its unaudited half-year results for the six months ended 30 June. Across the period, the Company advanced its proprietary ChemoSeed drug delivery technology and opened its Phase 2 clinical trial. CRISM’s initial therapeutic focus is in glioblastoma, an aggressive form of brain tumour, owing to the significant unmet need and attractive market size, estimated at $2.5bn in 2026 (rising to $5.0bn in 2033). The Company raised £2.745m in May 2026 and net cash at 18 September 2026 was £1.9m.
Eco Buildings Group 9.60p £14.32m (ECOB.L)
The AI technology-led housing manufacturing Company announced that it has entered into a binding Strategic Investment Framework Agreement with Lumen Holdings Limited, a co-signatory to the Agreement, and with the Ministry of Interior (Hon. Abdoulie Sanyang) and the Ministry of Defence (Hon. Sering Modou Njie) of the Republic of The Gambia, for the establishment of the ECO Buildings West Africa AI-Powered Centre of Excellence in The Gambia. The Agreement creates the formal framework for what the Board considers to be the most significant international development in Eco's history to date. The Key Terms and Strategic Commitments include a minimum 10,000-home housing programme, including an initial phase and minimum order of 1,000 homes, as set out in the Agreement.
GETECH Group 3.50p £4.96m (GTC.L)
The locator of subsurface resources announced its unaudited interim results and report for the six months to 30 June. H1 2026 revenue of £2.4m (H1 2025: £2.1m), representing a 15% increase compared with the prior period. Annualised Recurring Revenue was £3.0m at 31 August 2026 and adjusted EBITDA profit of £0.2m (H1 2025: Adjusted EBITDA loss of £0.1m). The cash balance was £0.6m at 30 June (31 December 2025: £0.2m). Trading momentum remains positive and the Company is well placed to meet market expectations for FY 2026.
Invinity Energy Systems 19.25p £112.77m (IES.L)
The vanadium flow battery technology Company announced its unaudited consolidated results for the six months ended 30 June and an update on trading in the year to date. Customer Orders increased nearly threefold to 34.2 MWh during the period (H1 2025: 11.7 MWh). Revenue and Project Grant Income increased to £1.7m (H1 2025: £0.9m) and the loss for the Period increased by 14% to £12.1m (H1 2025: £10.6m) reflecting increased investment in R&D to deliver the Company's cost-down programme. Net Cash was £10.5m and the Company confirms that trading remains in line with management expectations for the full year, with revenue recognition expected to be strongly weighted towards H2 2026, subject to anticipated project delivery timings.
Iofina 55.00p £97.85m (IOF.L)
The Company involved in the exploration and production of iodine and manufacturers of specialty chemical products announced its unaudited Interim Results for the six months ended 30 June. Record H1 revenue of $31.3m, up 7% (H1 25: $29.2m), Profit Before Tax of $4.9m, up 196% on an adjusted basis (H1 25: $1.7m excluding subsidies $1.8m) and Net Cash of $7.2m (H1 25: Net Debt: $0.8m). Iofina stated that it expects to produce 460-485 MT of crystalline iodine in H2 2026 and the Board believes it is on track to meet market expectations for the full year.
MedPal AI 5.35p £46.99m (MPAL.L)
The AI-native digital health and pharmacy Company announced that it has conditionally raised gross proceeds of £5m at a price of 5.0 pence per share. The Company also provided an update on trading for September to date. Based on trading from 1 to 19 September 2026, the annualised revenue run rate is now over £35m. The net proceeds of the Placing will be applied to working capital for medication stock and expansion of the GLP-1 line.
Mothercare 0.13p £1.15m (MTC.L)
The British heritage brand announced an update on its financial outlook. Mothercare was notified by the liquidators of Mothercare UK Limited (which entered administration in 2019), that imminently a further £0.8m cash dividend will be paid to a wholly owned subsidiary of the Company. It does not materially change the outlook for the business nor the matters disclosed in the announcement of 18 September. At this stage the outcome of the review and the longer-term solvency of the Company remains highly uncertain.
What’s baking in the oven?
Potential IPOs WIP:***
5th August: 1947 Oil & Gas, the newly incorporated oil and gas production Company focused on acquiring, operating and growing a portfolio of producing assets in the US, announced its intention to IPO onto AIM. In connection with Admission, the Company has entered into a conditional agreement to acquire Renaissance Offshore, LLC, a privately held, Houston-based oil and gas production Company with interests in eleven fields located in the shallow-water Gulf of America. The Company is raising an updated amount of £40m and the expected market capitalisation of the Company on Admission will be £70m. Admission is expected to occur in mid-September.
Dual List WIP:***
18th August: Aimia Inc. (TSX: AIM; JSE: AII) the Canadian diversified conglomerate announced plans to dual list on AIM. It owns a selection of businesses which include: (i) an 100% interest in Cortland International Inc., a global designer, manufacturer and supplier of synthetic fiber ropes, nets, slings and tethers; a 10.85% indirect stake in Clear Media Limited, the largest operator of bus shelter advertising panels in China; and iii) the Company holds a portfolio of publicly listed securities amounting C$12m as of 30 June 2026. No capital is expected to be raised on Admission and deal details remain TBC.
Expected first day of dealings 22 September.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
